UK Cancer Diagnostics Market Size & Outlook, 2024-2030
UK cancer diagnostics market, 2018-2030 (US$M)
Related Markets
UK cancer diagnostics market highlights
- The UK cancer diagnostics market generated a revenue of USD 4,138.8 million in 2024 and is expected to reach USD 6,032.3 million by 2030.
- The UK market is expected to grow at a CAGR of 6.7% from 2025 to 2030.
- In terms of segment, public insurance was the largest revenue generating coverage in 2024.
- Public insurance is the most lucrative coverage segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2024 | USD 4,138.8 million |
| Market revenue in 2030 | USD 6,032.3 million |
| Growth rate | 6.7% (CAGR from 2025 to 2030) |
| Largest segment | Public insurance |
| Fastest growing segment | Public insurance |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Public insurance, Private |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, UK accounted for 3.8% of the global cancer diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 6,032.3 million by 2030.
Public insurance was the largest segment with a revenue share of 91.5% in 2024. Horizon Databook has segmented the UK cancer diagnostics market based on public insurance, private covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of sophisticated healthcare infrastructure, collaborations between key market players, and launch of novel products are anticipated to contribute to market growth in the UK. Government support & initiatives are expected to further propel the country’s cancer diagnostics market in the coming years.
Commercial partnerships between the government and key players for routine use of MCED tests in the country are likely to propel market growth further. For instance, in November 2020, GRAIL entered into a commercial partnership with the UK government for a - blood test.
This agreement was expected to enhance the company’s position in the market. Government bodies, such as the NHS, are undertaking measures to promote wide usage of these tests, make them cost-effective & available to everyone, save time, and reduce the risk of complications.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK cancer diagnostics market size, by coverage, 2018-2030 (US$M)
UK Cancer Diagnostics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
